Study findings, populations and outcomes, with a direct line back to each source.
54 cited sources192 recorded findingsStudy findings updated
AI-assisted research summary. These summaries are for general information. Read the original source for the full study and its limitations.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY-11.85%average difference between groups
Subcutaneous semaglutide reduced weight but increased stopping for adverse events
In adults without type 2 diabetes, subcutaneous semaglutide produced 11.85% greater body-weight reduction than placebo. Stopping because of adverse events was more likely with semaglutide than placebo.
This was a systematic review and meta-analysis of adults with overweight or obesity. The discontinuation estimate was a relative risk, not an absolute rate.
See the evidence
Percentage change in body weight with subcutaneous semaglutide versus placebo in adults with overweight or obesity without type 2 diabetes
MD -11.85% 95% CI: -12.81% to -10.90%
Naz, Faryal et al.. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.. Medicine. 2026.
Treatment discontinuation due to adverse events with subcutaneous semaglutide versus placebo in adults with overweight or obesity without type 2 diabetes
RR 2.62 95% CI: 1.70-4.03
Naz, Faryal et al.. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.. Medicine. 2026.
Semaglutide lowered a broad kidney-outcome composite
16%lower relative hazard
Versus placebo, semaglutide had a 16% lower relative hazard of persistent ≥50% decline in estimated kidney filtration, kidney failure, kidney-related death, or cardiovascular-related death.
This prespecified analysis pooled SELECT, FLOW, and SOUL participants. Their baseline characteristics and semaglutide doses and routes differed.
See the evidence
16% lower relative hazard, calculated from HR 0.84. This is not an absolute percentage-point difference.
Primary composite of persistent ≥50% eGFR reduction, kidney failure, kidney-related death, or cardiovascular-related death with semaglutide versus placebo in the prespecified pooled SELECT, FLOW, and SOUL analysis; 973 versus 1134 first events. The trials differed in participants' baseline characteristics and in semaglutide dose and route.
HR 0.84 95% CI: 0.77-0.91
Mann, Johannes F E et al.. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.. The lancet. Diabetes & endocrinology. 2026.
In FLOW, once-weekly subcutaneous semaglutide 1 mg versus placebo was reported to reduce all-cause mortality by 20%.
Patients had type 2 diabetes and chronic kidney disease and received background guideline-directed therapy. This result is available here through an Australian narrative multidisciplinary review of FLOW, not a new trial analysis.
See the evidence
All-cause mortality with once-weekly subcutaneous semaglutide 1 mg versus placebo in the FLOW trial, among patients with type 2 diabetes and CKD receiving background guideline-directed therapy
20% reduction
Pedagogos, Eugenia et al.. Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.. Internal medicine journal. 2026.
Semaglutide had a lower hypoglycemia risk than insulin glargine
47%lower relative risk
In adults with type 2 diabetes uncontrolled on oral drugs, once-weekly semaglutide had a 47% lower relative risk of low blood sugar (hypoglycemia) than insulin glargine.
This came from a systematic review and pairwise meta-analysis, which classified the hypoglycemia finding as moderate-certainty evidence.
See the evidence
47% lower relative risk, calculated from RR 0.53. This is not an absolute percentage-point difference.
Hypoglycemia risk with semaglutide versus insulin glargine; moderate-certainty evidence
RR 0.53
Aljulajil, Faisal A et al.. Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.. Cureus. 2026.
Weight regain followed stopping semaglutide treatment
7.19%
Across six studies, mean body-weight regain from treatment end to follow-up after stopping semaglutide 2.4 mg was 7.19%.
This was a systematic review and meta-analysis. A common follow-up duration is not available in this summary, limiting interpretation of how quickly regain occurred.
See the evidence
Pooled mean percentage body-weight regain from end of treatment to follow-up after stopping semaglutide 2.4 mg, based on six studies
7.19% 95% CI: 6.42-7.96
Patel, Henna et al.. Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.. Cureus. 2026.
Gastrointestinal discontinuations were numerically higher with semaglutide
4.5% vs 1.1%
In FLOW, treatment stopping specifically for gastrointestinal adverse events was 4.5% with semaglutide versus 1.1% with placebo.
FLOW participants had chronic kidney disease. Overall adverse-event discontinuation proportions were descriptively similar within kidney-function subgroups. Safety was selectively collected, and subgroup comparisons had no formal inferential testing.
Study details & original results
Tuttle, Katherine R et al.. Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial.. Kidney international. 2026.
Descriptive incidence of treatment discontinuation specifically due to gastrointestinal adverse events with semaglutide versus placebo in FLOW, reported as more frequent with semaglutide regardless of baseline eGFR.
4.5% vs 1.1%
Descriptive incidence of treatment discontinuation due to adverse events with semaglutide versus placebo among FLOW participants with baseline eGFR at least 60 mL/min/1.73 m²; no inferential comparison was reported.
11.2% vs 11.3%
Descriptive incidence of treatment discontinuation due to adverse events with semaglutide versus placebo among FLOW participants with baseline eGFR below 30 mL/min/1.73 m²; no inferential comparison was reported.
High-dose initiation was associated with earlier discontinuation
Starting off-label injectable semaglutide at least 1.0 mg/week was associated with earlier treatment discontinuation; the comparison group is not available in this summary.
This retrospective observational analysis used claims from commercially insured US patients. Medication-taking behavior and reasons for stopping were not directly captured.
Study details & original results
Belalcazar, L Maria et al.. Real-World Semaglutide Initiation Behaviours in the United States: Impact on Early Treatment Discontinuation and on 1-Year Persistence.. Diabetes, obesity & metabolism. 2026.
Adjusted association between off-label high-dose injectable semaglutide initiation (at least 1.0 mg/week) and early treatment discontinuation; the observational analysis adjusted for age, obesity status, comorbidity measures, and cost.
Real-world exposure was shorter than trial treatment periods
approximately 4.6 months
Median exposure reported jointly for semaglutide and tirzepatide was approximately 4.6 months, versus 72 weeks cited as typically needed for peak randomized-trial benefit.
This observational EHR result is not semaglutide-specific. Pharmacy data may not capture actual adherence, and follow-up timing was not standardized.
Study details & original results
Ruan, Xiaoyang et al.. Current status of anti-obesity medications and performance, an EHR based survey.. BMC endocrine disorders. 2026.
Median real-world exposure duration reported jointly for semaglutide and tirzepatide, substantially shorter than the 72-week duration cited as typically required for peak RCT benefit.
A tirzepatide price change coincided with switching to semaglutide
9.26 percentage-point increase
Switching from tirzepatide to semaglutide increased by 9.26 percentage points around the price change and subsequently attenuated.
This interrupted-time-series analysis involved self-paying UK adults with overweight or obesity. The observational design cannot establish that the price change caused switching.
Study details & original results
Dix, Sophie et al.. Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.. Diabetes, obesity & metabolism. 2026.
Increase in tirzepatide-to-semaglutide switching around the price change; the increase subsequently attenuated, and sensitivity analyses supported anticipatory changes in August 2025.
Descriptive incidence of serious adverse events with semaglutide versus placebo among FLOW participants with baseline eGFR at least 60 mL/min/1.73 m²; safety data were collected selectively.
Descriptive incidence of serious adverse events with semaglutide versus placebo among FLOW participants with baseline eGFR below 30 mL/min/1.73 m²; safety data were collected selectively.
Descriptive incidence of treatment discontinuation due to adverse events with semaglutide versus placebo among FLOW participants with baseline eGFR at least 60 mL/min/1.73 m²; no inferential comparison was reported.
Descriptive incidence of treatment discontinuation due to adverse events with semaglutide versus placebo among FLOW participants with baseline eGFR below 30 mL/min/1.73 m²; no inferential comparison was reported.
Descriptive incidence of treatment discontinuation specifically due to gastrointestinal adverse events with semaglutide versus placebo in FLOW, reported as more frequent with semaglutide regardless of baseline eGFR.
Belalcazar, L Maria et al.. Real-World Semaglutide Initiation Behaviours in the United States: Impact on Early Treatment Discontinuation and on 1-Year Persistence.. Diabetes, obesity & metabolism. 2026.
Adjusted association between off-label high-dose injectable semaglutide initiation (at least 1.0 mg/week) and early treatment discontinuation; the observational analysis adjusted for age, obesity status, comorbidity measures, and cost.
Real-world weight loss associated with semaglutide across two EHR cohorts; the abstract did not specify a semaglutide-specific sample size or assessment time point.
Added
up to 6.2% median weight loss (IQR 11%)Source [53]
Median real-world exposure duration reported jointly for semaglutide and tirzepatide, substantially shorter than the 72-week duration cited as typically required for peak RCT benefit.
Observational association between metformin co-therapy and attenuated weight regain compared with semaglutide or tirzepatide monotherapy; the range was not reported separately for semaglutide.
Dix, Sophie et al.. Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.. Diabetes, obesity & metabolism. 2026.
Proportion initiating semaglutide through a single UK telehealth provider from May 2024 to January 2026; 90.2% initiated tirzepatide, so these provider-specific proportions should not be generalized to all UK treatment.
Segmented interrupted-time-series estimate for semaglutide initiation in September 2025 relative to the projected pre-interruption trend, around the tirzepatide list-price increase.
Increase in tirzepatide-to-semaglutide switching around the price change; the increase subsequently attenuated, and sensitivity analyses supported anticipatory changes in August 2025.
Linear mixed-effects model estimate of 12-month weight loss with semaglutide among self-paying UK telehealth patients contributing follow-up (n=979), with limited adjunctive lifestyle support; this was an observational trajectory estimate rather than a randomized treatment comparison.
Gao, Leili et al.. Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial.. Diabetes, obesity & metabolism. 2026.
Week-44 body-weight reduction with HD1916 versus reference semaglutide in a randomized, open-label Phase III trial among Chinese adults with obesity without diabetes; the confidence interval was within the prespecified equivalence margin of ±4.16%.
Added
13.1% vs 14.4%; estimated treatment difference 1.35%95% CI: -0.02 to 2.72Source [49]
Descriptive proportions achieving at least 5% weight loss with HD1916 versus reference semaglutide at week 44; the abstract described the proportions as comparable.
Descriptive proportions achieving at least 10% weight loss with HD1916 versus reference semaglutide at week 44; the abstract described the proportions as comparable.
Al-Nusair, Mohammed et al.. Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.. Journal of diabetes and metabolic disorders. 2026.
Propensity-score-matched association between tirzepatide versus semaglutide and the composite of acute myocardial infarction, stroke, and acute heart failure among patients with type 2 diabetes; the composite HR is reproduced as reported despite its point estimate falling outside the reported confidence interval.
Added
HR 0.9; 4.6% vs 5.5%; ARD -0.9%HR 95% CI: 0.92-0.96; ARD 95% CI: -1.01 to -0.77Source [50]
Propensity-score-matched association between tirzepatide versus semaglutide and all-cause mortality among patients with type 2 diabetes.
Added
HR 0.8; 0.6% vs 0.9%; ARD -0.3%HR 95% CI: 0.74-0.84; ARD 95% CI: -0.33 to -0.24Source [50]
SOURCE 483 findings
Pedagogos, Eugenia et al.. Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.. Internal medicine journal. 2026.
Major kidney disease events with once-weekly subcutaneous semaglutide 1 mg versus placebo in the FLOW trial, among patients with type 2 diabetes and CKD receiving background guideline-directed therapy
Major adverse cardiovascular events with once-weekly subcutaneous semaglutide 1 mg versus placebo in the FLOW trial, among patients with type 2 diabetes and CKD receiving background guideline-directed therapy
All-cause mortality with once-weekly subcutaneous semaglutide 1 mg versus placebo in the FLOW trial, among patients with type 2 diabetes and CKD receiving background guideline-directed therapy
Yuan, Yahui et al.. GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.. Drugs. 2026.
MACE with GLP-1 RAs in the phenotype-based HFpEF analysis; this is a class-level, not semaglutide-specific, estimate, and the abstract indicates that HFpEF benefits were predominantly observed among overweight or obese individuals.
Hospitalization for heart failure with GLP-1 RAs in the phenotype-based HFpEF analysis; this is a class-level, not semaglutide-specific, estimate, and the abstract indicates that HFpEF benefits were predominantly observed among overweight or obese individuals.
Composite of cardiovascular death or worsening heart-failure events with GLP-1 RAs in the phenotype-based HFpEF analysis; this is a class-level, not semaglutide-specific, estimate.
Cardiovascular death with GLP-1 RAs in HFrEF; no significant reductions were observed for hospitalization, cardiovascular death or worsening-HF composite, all-cause mortality, or MACE.
Cardiovascular death with GLP-1 RAs in trial-level analyses of heart-failure subgroups from cardiovascular outcome trials; the abstract reported p=0.05, and this is not a semaglutide-specific estimate.
Myocardial infarction or nonfatal myocardial infarction with GLP-1 RAs in trial-level analyses of heart-failure subgroups from cardiovascular outcome trials; the abstract reported p=0.046, and this is not a semaglutide-specific estimate.
Median peak body-weight loss among 7,594 SELECT participants with obesity and preexisting atherosclerotic disease without diabetes who received semaglutide continuously for at least 1 year; this selected cohort represented 86.3% of participants randomized to semaglutide.
Added
12.5% (IQR 7.9-17.9), reached after a median of 19 months (IQR 10-30)Source [45]
Association between maximum semaglutide dose of 0.24 mg versus 2.4 mg and median peak percentage body-weight loss among continuously treated participants; this was not a randomized dose comparison.
Added
6.0% (IQR 1.9-10.9) vs. 13.3% (IQR 9.0-18.4)Source [45]
All 3 findings from this source
Median peak percentage body-weight loss among semaglutide-treated women versus men in the continuously treated SELECT cohort; this is an associated subgroup difference rather than a randomized sex comparison.
Added
16.6% (IQR 10.9-23.4) vs. 12.4% (IQR 8.4-16.9)Source [45]
SOURCE 461 finding
Cummings, Jeffrey L et al.. Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications.. The journal of prevention of Alzheimer's disease. 2026.
Nominally significant decreases in the CSF astroglial-activation biomarkers YKL-40 and GFAP with semaglutide in the EVOKE/EVOKE+ early Alzheimer’s disease trials; the changes were small and did not correlate with disease progression.
Change in hsCRP considered separately as a potential mediator of semaglutide's MACE reduction; the confidence interval was wide and extended above 100%.
Change in HbA1c considered separately as a potential mediator of semaglutide's MACE reduction; the estimate was highly imprecise and its confidence interval included zero.
Body-weight change considered separately as a potential mediator of semaglutide's MACE reduction; the confidence interval included zero, and supplementary analyses suggested that the estimate was potentially unreliable because the weight-change–MACE relationship differed between treatment arms.
Joint mediation estimate for all investigated potential mediators combined; the confidence interval was extremely wide and included zero, so the analysis could not determine with certainty how much of semaglutide's MACE reduction these factors explained.
Joint mediation estimate when body weight and waist circumference were excluded; the confidence interval included zero and was too wide to establish a definitive mediated proportion.
Amamoo, James et al.. Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease.. Advances in therapy. 2026.
Greater model-estimated HbA1c reduction at 12 months with once-weekly semaglutide versus selected oral glucose-lowering medications among patients with T2D and CKD who were ineligible for or had a suboptimal response to SGLT2 inhibitors; P<0.05, with effects largely sustained during follow-up.
Association between once-weekly semaglutide and the composite of dialysis, kidney transplantation, sustained eGFR below 15 mL/min/1.73 m², or all-cause death versus selected oral glucose-lowering medications. The renal-outcome sample excluded patients with eGFR below 25 mL/min/1.73 m² during the prior six months and those with baseline dialysis, kidney transplantation, or kidney failure.
AlAraibi, Ahmed J et al.. The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2026.
Pooled improvement in KCCQ clinical summary score with semaglutide or tirzepatide among patients with HFpEF and obesity; the primary analysis was restricted to three randomized trials.
Pooled improvement in 6-minute walk distance with semaglutide or tirzepatide among patients with HFpEF and obesity; the estimate is not semaglutide-specific.
Pooled risk of worsening heart-failure events with semaglutide or tirzepatide among patients with HFpEF and obesity; this mixed-agent estimate is not attributable to semaglutide alone.
Pooled body-weight change with semaglutide or tirzepatide among patients with HFpEF and obesity; heterogeneity was high (I²=93%), and the estimate is not semaglutide-specific.
Sun, Hong et al.. Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.. Diabetes, obesity & metabolism. 2026.
NAION risk with semaglutide versus non-GLP-1RA treatments in a network meta-analysis; semaglutide had the highest estimated risk among the evaluated GLP-1 receptor agonists.
Ostrominski, John W et al.. Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.. JAMA cardiology. 2026.
Primary composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke with semaglutide versus placebo among participants classified as not frail (FI ≤0.210).
Primary composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke with semaglutide versus placebo among more-frail participants (FI 0.211-0.310).
Primary composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke with semaglutide versus placebo among the most-frail participants (FI ≥0.311).
Categorical frailty-index interaction test for semaglutide's effect on the primary cardiovascular composite; the abstract reported that benefits appeared consistent across categories.
Frailty-category interaction test for semaglutide's effect on the composite heart-failure outcome; the abstract reported reduction regardless of FI category.
Interaction between baseline frailty and semaglutide's effect on EQ-5D-5L health-related quality-of-life scores, with apparently larger benefits at higher FI.
Interaction between baseline frailty and semaglutide-versus-placebo hazard ratios for adverse events leading to permanent discontinuation; comparative HRs appeared lower at higher baseline FI, but stratum-specific HRs were not reported in the abstract.
Zhou, Ziyan et al.. Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease.. Diabetes, obesity & metabolism. 2026.
Composite kidney outcome with dapagliflozin versus semaglutide in a frequentist network meta-analysis of randomized trials among adults with type 2 diabetes and diabetic kidney disease; most other efficacy comparisons between active monotherapies were not statistically significant.
Moubarak, Elsayed S et al.. Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.. Journal of psychopharmacology (Oxford, England). 2026.
Body-weight reduction with semaglutide in a GLP-1 RA type subgroup analysis of randomized trials involving antipsychotic-treated patients; between-agent subgroup differences for weight and BMI were significant at p<0.05.
BMI reduction with semaglutide in a GLP-1 RA type subgroup analysis of randomized trials involving antipsychotic-treated patients; between-agent subgroup differences for weight and BMI were significant at p<0.05.
Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.
Mean body-weight change at 72 weeks with tirzepatide versus semaglutide in a phase 3b open-label, randomized, active-controlled trial of adults with overweight or obesity.
Range of adjusted between-group weight-loss differences across retrospective real-world cohorts; the advantage was smaller than in the trial and most pronounced at stringent weight-reduction thresholds. Substantial heterogeneity precluded meta-analysis, and four cohorts had serious risk of bias, principally from unadjusted confounding.
Added
approximately 2.3-4.4 percentage points favoring tirzepatideSource [37]
SOURCE 362 findings
Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Total weight loss at 12 months with semaglutide in adults treated with an incretin receptor agonist at least one year after metabolic bariatric surgery; substantial heterogeneity across studies requires cautious interpretation.
Mean difference in total weight loss at 6 months for tirzepatide versus semaglutide after metabolic bariatric surgery; substantial heterogeneity across studies requires cautious interpretation.
Moiz, Areesha et al.. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.. Annals of internal medicine. 2026.
Placebo-subtracted weight loss with subcutaneous semaglutide in an updated systematic review of RCTs among adults with overweight or obesity without diabetes; heterogeneity precluded quantitative synthesis.
Placebo-subtracted weight loss with oral semaglutide in an updated systematic review of RCTs among adults with overweight or obesity without diabetes; heterogeneity precluded quantitative synthesis.
Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Estimated monthly weight regain after discontinuation across semaglutide or tirzepatide studies with observed follow-up ranging from 4 to 52 weeks; this pooled estimate is not semaglutide-specific.
Projected time to regain 50% of the initial weight loss after semaglutide or tirzepatide discontinuation, based on a constant linear-regain model; estimates beyond 52 weeks were extrapolated and require cautious interpretation.
Projected time to return to baseline weight after semaglutide or tirzepatide discontinuation, based on a constant linear-regain model; this exceeds the observed follow-up and is a model-based extrapolation.
McIntyre, Roger S et al.. Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.. JAMA psychiatry. 2026.
Four-year all-cause mortality among propensity-score-matched adults with serious mental illness initiating any GLP-1 RA versus an SGLT2 inhibitor; this is a class-level, not semaglutide-specific, estimate.
Absolute four-year all-cause mortality difference among matched adults with serious mental illness initiating any GLP-1 RA versus an SGLT2 inhibitor; this is a class-level estimate.
Added
4.91% vs 6.45%; ARD -1.54 percentage points95% CI: -1.68 to -1.39 percentage pointsSource [32]
All 8 findings from this source
One-year all-cause mortality in a separately matched serious-mental-illness cohort initiating any GLP-1 RA versus an SGLT2 inhibitor; this is a class-level, not semaglutide-specific, estimate.
Absolute one-year all-cause mortality difference in a separately matched serious-mental-illness cohort initiating any GLP-1 RA versus an SGLT2 inhibitor; this is a class-level estimate.
Added
1.46% vs 2.84%; ARD -1.38 percentage points95% CI: -1.47 to -1.29 percentage pointsSource [32]
Three-point MACE with semaglutide versus SGLT2 inhibitor initiation among participants with serious mental illness and type 2 diabetes.
Mortality with semaglutide versus SGLT2 inhibitor initiation in the major-depressive-disorder subgroup with type 2 diabetes in an exploratory 10-year analysis.
Proportion of reported adverse events involving abortion or pregnancy loss; this is a proportion of reported events, not the risk among exposed pregnancies.
FAERS reporting odds for pregnancy, puerperium, and perinatal conditions with semaglutide versus other medications; this is a disproportionality signal and not a causal risk estimate.
FAERS reporting odds for gastrointestinal disorders with semaglutide versus other medications in pregnancy-related reports; this is a disproportionality signal and not a causal risk estimate.
SMQ-based FAERS reporting odds for termination of pregnancy and risk of abortion with semaglutide versus other medications; this is a reporting signal and does not establish increased clinical risk or causation.
Banerjee, Mainak et al.. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.. Obesity (Silver Spring, Md.). 2026.
Major adverse liver outcomes with tirzepatide versus injectable semaglutide among adults with overweight or obesity and type 2 diabetes over a median follow-up of approximately 17 months; no significant difference was observed.
Added
HR 1.04; IR 4.05 vs. 4.04 per 1000 PY95% CI: 0.88-1.23Source [31]
Major adverse liver outcomes with tirzepatide versus injectable semaglutide in the MASLD subgroup; the abstract reported a comparable risk profile.
Added
HR 1.03; IR 9.97 vs. 10.03 per 1000 PY95% CI: 0.75-1.42Source [31]
All 3 findings from this source
Major adverse liver outcomes with tirzepatide versus injectable semaglutide in the as-treated sensitivity analysis.
Khani, Elnaz et al.. Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.. Journal of clinical pharmacology. 2026.
NAION risk with semaglutide versus non-semaglutide treatment in a meta-analysis of observational cohorts; heterogeneity was high (I2=91%), and the authors stated that randomized trials are needed for a clear conclusion.
Fibrosis improvement by at least one stage with semaglutide versus placebo after 72 weeks in MASH; the relationship between treatment-induced histologic improvement and reduced clinical outcomes remains unproven.
Plutzky, Jorge et al.. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.. Circulation. 2026.
Semaglutide-associated change in hsCRP at 104 weeks among patients with established atherosclerotic cardiovascular disease and overweight or obesity but without diabetes in the prespecified SELECT analysis.
Hypertension-related treatment-emergent adverse events with semaglutide in patients treated for T2DM or obesity; the overall association was not statistically significant (p=0.233), although the abstract noted unquantified potential protective signals in high-dose subgroups.
Hypotension-related treatment-emergent adverse events with semaglutide in patients treated for T2DM or obesity; the overall association was not statistically significant (p=0.232), although the abstract noted unquantified potential protective signals in high-dose subgroups.
Murugadoss, Karthik et al.. GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk.. Biology methods & protocols. 2026.
First recorded Alzheimer's disease diagnosis after GLP-1-based incretin initiation versus non-GLP-1 antidiabetic medication initiation in the primary matched cohort of adults aged at least 50 years with a documented Alzheimer's disease risk factor; class-level observational association.
First recorded Alzheimer's disease diagnosis among semaglutide initiators versus matched non-GLP-1 antidiabetic medication initiators in an observational analysis with 23,675 patients per arm; q=0.02.
Tseng, Ting-Chun et al.. Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2026.
Composite cardiovascular outcome with metabolic and bariatric surgery versus semaglutide during up to 5 years of follow-up among adults with obesity without T2DM.
Added
HR 0.402; 4.4% vs 6.6%95% CI: 0.356-0.454Source [25]
Composite cardiovascular outcome with metabolic and bariatric surgery versus semaglutide during up to 5 years of follow-up among adults with obesity and T2DM.
Added
HR 0.421; 9.0% vs 14.6%95% CI: 0.381-0.465Source [25]
All 4 findings from this source
Heart-failure risk with metabolic and bariatric surgery versus semaglutide among adults with obesity without T2DM.
Guo, Lixin et al.. Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.. The lancet. Diabetes & endocrinology. 2026.
Week-44 bodyweight change with once-weekly subcutaneous semaglutide 2.4 mg versus placebo, both plus lifestyle intervention, in adults from mainland China and Taiwan meeting local overweight or obesity BMI criteria; missing data were imputed with washout multiple imputation.
Added
-12.1% vs -2.2%; estimated treatment difference -9.9 percentage points95% CI: -11.8 to -8.0 percentage pointsSource [24]
Odds of achieving at least 5% bodyweight reduction by week 44 with semaglutide 2.4 mg versus placebo, both plus lifestyle intervention, in adults from mainland China and Taiwan meeting local overweight or obesity BMI criteria.
Added
OR 14.8; 80.5% vs 24.4%95% CI: 7.4 to 29.6Source [24]
All 3 findings from this source
Descriptive incidence of any adverse event with semaglutide 2.4 mg versus placebo among participants receiving treatment; gastrointestinal disorders were the most common adverse events.
Jiménez-Mausbach, Martí et al.. Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.. Alzheimer's & dementia (Amsterdam, Netherlands). 2026.
Increase through week 104 in dSST-predicted 5-year dementia risk with semaglutide versus placebo among adults aged at least 65 years with overweight or obesity and cardiovascular disease without diabetes; this represented a 26.0% lower predicted event rate and a 2.5-fold smaller increase.
Increase through week 104 in dSST-predicted 20-year dementia risk with semaglutide versus placebo among adults aged at least 65 years with overweight or obesity and cardiovascular disease without diabetes; this represented an 8.8% lower predicted risk and a 1.67-fold smaller increase.
Reduction in the odds of a higher dSST dementia-risk classification with semaglutide versus placebo in the post hoc SELECT analysis; β=-0.44 and P<0.001.
Qasim, Abeer et al.. The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents.. Frontiers in gastroenterology (Lausanne, Switzerland). 2026.
Mann, Johannes F E et al.. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.. The lancet. Diabetes & endocrinology. 2026.
Primary composite of persistent ≥50% eGFR reduction, kidney failure, kidney-related death, or cardiovascular-related death with semaglutide versus placebo in the prespecified pooled SELECT, FLOW, and SOUL analysis; 973 versus 1134 first events. The trials differed in participants' baseline characteristics and in semaglutide dose and route.
Narrower secondary kidney composite excluding cardiovascular-related death with semaglutide versus placebo in the prespecified pooled SELECT, FLOW, and SOUL analysis; 347 versus 416 first events. The trials differed in participants' baseline characteristics and in semaglutide dose and route.
Pałka, Wiktoria et al.. Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.. Journal of endocrinological investigation. 2026.
Average incremental efficacy benefit of semaglutide 7.2 mg over 2.4 mg over at least one year; the benefit was characterized as modest, percentage-bodyweight superiority was significant only in the diabetes subgroup, and tolerability and patient preferences should be considered.
Reduction in triptan consumption among prevalent users; the abstract attributes the overall decrease mainly to lower consumption among existing users rather than a change in monthly rates of new users.
Kamrul-Hasan, A B M et al.. Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.. Obesity science & practice. 2026.
Percent body-weight change with high-dose oral semaglutide versus placebo in adults with overweight or obesity without diabetes; low-to-moderate-certainty network estimate, with comparative inference constrained by the absence of head-to-head trials.
BMI change with high-dose oral semaglutide versus placebo in adults with overweight or obesity without diabetes; low-to-moderate-certainty network estimate, with no head-to-head comparisons.
Waist-circumference change with high-dose oral semaglutide versus placebo in adults with overweight or obesity without diabetes; low-to-moderate-certainty network estimate, with no head-to-head comparisons.
Dutta, Deep et al.. Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2026.
Pooled absolute proportion of semaglutide-treated patients with ESRD experiencing nausea; the estimate was highly imprecise and heterogeneous (I²=73.6%).
Thorsteinsdottir, Sigrun et al.. Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.. Pediatric obesity. 2026.
No statistically significant modification of treatment response by neurodevelopmental-disorder status was detected among 56 Pediatric Obesity Center participants; the analysis was underpowered and should not be interpreted as evidence of equivalent response.
Naz, Faryal et al.. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.. Medicine. 2026.
Treatment discontinuation due to adverse events with subcutaneous semaglutide versus placebo in adults with overweight or obesity without type 2 diabetes
Hwang, Inyoung et al.. Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.. Drug design, development and therapy. 2026.
Adjusted relative likelihood of achieving ≥15% weight loss with semaglutide versus liraglutide among adults with obesity in a retrospective real-world cohort.
Key preregistered secondary outcome of heavy drinking days during the last 4 treatment weeks with oral semaglutide versus placebo in treatment-seeking adults with moderate-to-severe alcohol use disorder; laboratory-assessed craving and drinks per day were not significantly reduced.
Exploratory comparison of the proportion reducing World Health Organization risk drinking level by at least one category with oral semaglutide versus placebo; the abstract did not report group percentages.
Rodbard, Helena W et al.. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).. Diabetes, obesity & metabolism. 2026.
Severe hypoglycaemia occurred at a lower rate with semaglutide 2.0 mg plus dose-reduced insulin glargine versus dose-titrated insulin glargine at 40 weeks (p=0.02).
Gastrointestinal adverse-event counts were higher with semaglutide 2.0 mg plus dose-reduced insulin glargine than with dose-titrated insulin glargine; these are event counts rather than participant-level incidence rates, and the abstract reported no new safety concerns.
Aljulajil, Faisal A et al.. Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.. Cureus. 2026.
HbA1c reduction with once-weekly semaglutide 1.0 mg versus insulin glargine or other GLP-1 receptor agonists in insulin-naive adults with T2DM uncontrolled on oral drugs; low-certainty evidence
Khan, Suleman et al.. Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.. Medicine. 2026.
Azzam, Ahmed Y et al.. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.. JACC. Advances. 2026.
Inzucchi, Silvio E et al.. Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?. The Journal of clinical endocrinology and metabolism. 2026.
Cannon, Ethan J et al.. Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.. British journal of clinical pharmacology. 2026.
Zhou, Xiao-Yu et al.. Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2026.
Ahmed, Faizan et al.. GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.. Journal of clinical medicine. 2026.
Loomba, Rohit et al.. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.. The lancet. Gastroenterology & hepatology. 2026.
Proportion achieving improvement in liver fibrosis without MASH worsening with semaglutide 2.4mg versus placebo at week 52 in MASH patients with F2-F4c fibrosis
Nong, Kailei et al.. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.. BMJ (Clinical research ed.). 2026.
Chen, Hsin-Yu et al.. Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2026.
Browse the 54 original sourcesThe full bibliography behind this monitor.
[1]
Nong, Kailei et al.. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.. BMJ (Clinical research ed.). 2026.
Chen, Hsin-Yu et al.. Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2026.
Ahmed, Faizan et al.. GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.. Journal of clinical medicine. 2026.
Loomba, Rohit et al.. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.. The lancet. Gastroenterology & hepatology. 2026.
Cannon, Ethan J et al.. Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.. British journal of clinical pharmacology. 2026.
Zhou, Xiao-Yu et al.. Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2026.
Inzucchi, Silvio E et al.. Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?. The Journal of clinical endocrinology and metabolism. 2026.
Azzam, Ahmed Y et al.. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.. JACC. Advances. 2026.
Aljulajil, Faisal A et al.. Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.. Cureus. 2026.
Khan, Suleman et al.. Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.. Medicine. 2026.
Rodbard, Helena W et al.. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).. Diabetes, obesity & metabolism. 2026.
Hwang, Inyoung et al.. Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.. Drug design, development and therapy. 2026.
Naz, Faryal et al.. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.. Medicine. 2026.
Thorsteinsdottir, Sigrun et al.. Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.. Pediatric obesity. 2026.
Dutta, Deep et al.. Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2026.
Pałka, Wiktoria et al.. Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.. Journal of endocrinological investigation. 2026.
Kamrul-Hasan, A B M et al.. Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.. Obesity science & practice. 2026.
Qasim, Abeer et al.. The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents.. Frontiers in gastroenterology (Lausanne, Switzerland). 2026.
Mann, Johannes F E et al.. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.. The lancet. Diabetes & endocrinology. 2026.
Jiménez-Mausbach, Martí et al.. Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.. Alzheimer's & dementia (Amsterdam, Netherlands). 2026.
Guo, Lixin et al.. Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.. The lancet. Diabetes & endocrinology. 2026.
Tseng, Ting-Chun et al.. Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2026.
Murugadoss, Karthik et al.. GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk.. Biology methods & protocols. 2026.
Plutzky, Jorge et al.. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.. Circulation. 2026.
Khani, Elnaz et al.. Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.. Journal of clinical pharmacology. 2026.
Banerjee, Mainak et al.. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.. Obesity (Silver Spring, Md.). 2026.
McIntyre, Roger S et al.. Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.. JAMA psychiatry. 2026.
Moiz, Areesha et al.. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.. Annals of internal medicine. 2026.
Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.
Moubarak, Elsayed S et al.. Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.. Journal of psychopharmacology (Oxford, England). 2026.
Ostrominski, John W et al.. Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.. JAMA cardiology. 2026.
Zhou, Ziyan et al.. Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease.. Diabetes, obesity & metabolism. 2026.
Sun, Hong et al.. Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.. Diabetes, obesity & metabolism. 2026.
AlAraibi, Ahmed J et al.. The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2026.
Amamoo, James et al.. Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease.. Advances in therapy. 2026.
Cummings, Jeffrey L et al.. Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications.. The journal of prevention of Alzheimer's disease. 2026.
Yuan, Yahui et al.. GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.. Drugs. 2026.
Pedagogos, Eugenia et al.. Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.. Internal medicine journal. 2026.
Gao, Leili et al.. Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial.. Diabetes, obesity & metabolism. 2026.
Al-Nusair, Mohammed et al.. Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.. Journal of diabetes and metabolic disorders. 2026.
Dix, Sophie et al.. Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.. Diabetes, obesity & metabolism. 2026.
Belalcazar, L Maria et al.. Real-World Semaglutide Initiation Behaviours in the United States: Impact on Early Treatment Discontinuation and on 1-Year Persistence.. Diabetes, obesity & metabolism. 2026.
Study findings are generated with AI assistance and have not been reviewed by a clinician. The date on each finding records when it was added to this monitor; it is not the publication date or a clinical review date.
This monitor does not offer individual treatment advice. Bring personal health questions to a qualified clinician.
Download the findings and bibliography displayed in this page snapshot. Values and confidence intervals remain as reported text; this is not a pooled estimate or a systematic review. Product-label observations and editorial takeaways are excluded.
These findings may omit evidence or contain errors and have not been reviewed by a clinician. A citation or download does not establish source verification. Read the original studies for their methods and limitations.
“Added” dates record entry into the monitor, not publication or clinical review. A null original acquisition or derivation means its historical record is unknown; a current record or verification has its own observation time. The SHA-256 snapshot identifier binds the downloadable public fields. CSV includes finding rows and bibliography-only source rows; JSON includes both lists. Spreadsheet-sensitive CSV cells begin with an apostrophe for safety; JSON preserves the original text.
For attribution, cite ModernDoc and the page URL, data update date and snapshot identifier in the download. Original studies retain their own rights; this download does not grant a licence to their full text.
Get a summary twice a month when this evidence changes
A short summary twice a month, when study findings on this topic change. If nothing changed, we don't email. Summaries use automated source and retraction checks and have not been reviewed by a clinician. No marketing. Subscribing covers GLP-1 receptor agonists, including its related monitor pages.
We'll first send one confirmation email — you're not subscribed until you click it. Subscribing signals an interest in GLP-1 receptor agonists; we treat that as sensitive: we store only your email address, this topic and the date you subscribed, never linked to any health record, and never sold. Temporary abuse counters use keyed identifiers and expire within 24 hours. Our email provider delivers the messages. Every email includes a one-click unsubscribe link. Sent by ModernDoc (moderndoc.co).